يعرض 1 - 7 نتائج من 7 نتيجة بحث عن '"Flavia Adler"', وقت الاستعلام: 1.40s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Supplementary Data from CRISPR Screening Identifies Mechanisms of Resistance to KRAS G12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

    المؤلفون: Anirudh Prahallad, Andreas Weiss, Hans Voshol, Grainne Kerr, Kathleen Sprouffske, Tina Yuan, David Ruddy, Morgane Meistertzheim, Malika Kazic-Legueux, Tina Kottarathil, Michelle Piquet, Yichen Cao, Laetitia Martinuzzi-Duboc, Alexandra Buhles, Flavia Adler, Salvatore Mannino, Luca Tordella, Laurent Sansregret, Sauveur-Michel Maira, Diana Graus Porta, Carmine Fedele, Saskia M. Brachmann

    مصطلحات موضوعية: Cancer, Therapeutic Research and Development, Methods and Technology, Drug Resistance, Lung Cancer, Preclinical Models, In vitro models of cancer, Xenograft models

    العلاقة: https://figshare.com/articles/journal_contribution/Supplementary_Data_from_CRISPR_Screening_Identifies_Mechanisms_of_Resistance_to_KRAS_sup_G12C_sup_and_SHP2_Inhibitor_Combinations_in_Non_Small_Cell_Lung_Cancer/24825255Test

    الإتاحة: https://doi.org/10.1158/0008-5472.24825255.v1Test
    https://figshare.com/articles/journal_contribution/Supplementary_Data_from_CRISPR_Screening_Identifies_Mechanisms_of_Resistance_to_KRAS_sup_G12C_sup_and_SHP2_Inhibitor_Combinations_in_Non_Small_Cell_Lung_Cancer/24825255Test

    View record in BASE

    أضف إلى المفضلة
  2. 2
    Supplementary Table S1 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

    المؤلفون: Diana Graus Porta, William R. Sellers, Francesco Hofmann, Jutta Blank, Pascal Furet, Robert Mah, Catherine Leblanc, Nicole Buschmann, Thomas Knoepfel, Audrey Kauffmann, Masato Murakami, Patrizia Barzaghi-Rinaudo, Youzhen Wang, Armin Wolf, Philippe Couttet, Heiko S. Schadt, Jacqueline Kinyamu-Akunda, Markus Wartmann, Mario Centeleghe, Dario Sterker, Michael Kiffe, Robin A. Fairhurst, Christelle Stamm, Alexandra Buhles, Flavia Adler, Andreas Weiss

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de614aa92fc53e000078388a9034229Test
    https://doi.org/10.1158/1535-7163.22506502.v1Test


    أضف إلى المفضلة
  3. 3
    Supplementary Materials and Methods from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

    المؤلفون: Diana Graus Porta, William R. Sellers, Francesco Hofmann, Jutta Blank, Pascal Furet, Robert Mah, Catherine Leblanc, Nicole Buschmann, Thomas Knoepfel, Audrey Kauffmann, Masato Murakami, Patrizia Barzaghi-Rinaudo, Youzhen Wang, Armin Wolf, Philippe Couttet, Heiko S. Schadt, Jacqueline Kinyamu-Akunda, Markus Wartmann, Mario Centeleghe, Dario Sterker, Michael Kiffe, Robin A. Fairhurst, Christelle Stamm, Alexandra Buhles, Flavia Adler, Andreas Weiss

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::855b9cca12680f3ffc27bb3edd85e4d5Test
    https://doi.org/10.1158/1535-7163.22506505.v1Test


    أضف إلى المفضلة
  4. 4
    Supplementary Figure S2 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

    المؤلفون: Diana Graus Porta, William R. Sellers, Francesco Hofmann, Jutta Blank, Pascal Furet, Robert Mah, Catherine Leblanc, Nicole Buschmann, Thomas Knoepfel, Audrey Kauffmann, Masato Murakami, Patrizia Barzaghi-Rinaudo, Youzhen Wang, Armin Wolf, Philippe Couttet, Heiko S. Schadt, Jacqueline Kinyamu-Akunda, Markus Wartmann, Mario Centeleghe, Dario Sterker, Michael Kiffe, Robin A. Fairhurst, Christelle Stamm, Alexandra Buhles, Flavia Adler, Andreas Weiss

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8a8adc6be4db10400fb7b3afdb43e38Test
    https://doi.org/10.1158/1535-7163.22506514.v1Test


    أضف إلى المفضلة
  5. 5
    Data from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

    المؤلفون: Diana Graus Porta, William R. Sellers, Francesco Hofmann, Jutta Blank, Pascal Furet, Robert Mah, Catherine Leblanc, Nicole Buschmann, Thomas Knoepfel, Audrey Kauffmann, Masato Murakami, Patrizia Barzaghi-Rinaudo, Youzhen Wang, Armin Wolf, Philippe Couttet, Heiko S. Schadt, Jacqueline Kinyamu-Akunda, Markus Wartmann, Mario Centeleghe, Dario Sterker, Michael Kiffe, Robin A. Fairhurst, Christelle Stamm, Alexandra Buhles, Flavia Adler, Andreas Weiss

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::13e8f6230bcc0ef53c3f3f3f81212e3cTest
    https://doi.org/10.1158/1535-7163.c.6538417.v1Test


    أضف إلى المفضلة
  6. 6
    Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

    المؤلفون: Christelle Stamm, Pierre Nimsgern, Thomas Knoepfel, Jasmin Wirth, Michel Niklaus, Diana Graus-Porta, Alberto Del Rio Espinola, Dario Sterker, Michael Kiffe, Nicolas Warin, Van Huy Luu, Mario Madoerin, Robert Mah, Jacqueline Kinyamu-Akunda, Robin Alec Fairhurst, Milen Todorov, Nicole Buschmann, Sebastien Ripoche, Nils Ostermann, Inga Galuba, Philippe Couttet, Catherine Leblanc, Alexandra Buhles, Jutta Blank, Flavia Adler, Wolfgang Jahnke, Chao Zou, Joerg Berghausen, Andreas Weiss, Pascal Furet, Heiko Schadt, Johannes Voshol, Markus Wartmann, Joerg Trappe

    المصدر: Journal of Medicinal Chemistry. 63:12542-12573

    مصطلحات موضوعية: Receptor complex, Pyridines, Sequence alignment, Molecular Dynamics Simulation, Piperazines, Mice, Structure-Activity Relationship, chemistry.chemical_compound, Dogs, Cell Line, Tumor, Drug Discovery, Animals, Structure–activity relationship, Receptor, Fibroblast Growth Factor, Type 4, Amino Acid Sequence, Cysteine, Kinase activity, Binding site, Protein Kinase Inhibitors, Cell Proliferation, Binding Sites, Liver Neoplasms, Hemithioacetal, Fibroblast growth factor receptor 4, Xenograft Model Antitumor Assays, Rats, chemistry, Biochemistry, Drug Design, Hepatocytes, Microsomes, Liver, Molecular Medicine, Half-Life

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e8386d5d1c6ff60ee10d825b90d6deTest
    https://doi.org/10.1021/acs.jmedchem.0c01019Test


    أضف إلى المفضلة
  7. 7
    FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

    المؤلفون: Armin Wolf, Andreas Weiss, Markus Wartmann, Pascal Furet, William R. Sellers, Alexandra Buhles, Patrizia Barzaghi-Rinaudo, Heiko Schadt, Catherine Leblanc, Robin Alec Fairhurst, Robert Mah, Mario Centeleghe, Jacqueline Kinyamu-Akunda, Philippe Couttet, Jutta Blank, Michael Kiffe, Nicole Buschmann, Dario Sterker, Audrey Kauffmann, Masato Murakami, Youzhen Wang, Diana Graus Porta, Flavia Adler, Thomas Knoepfel, Francesco Hofmann, Christelle Stamm

    المصدر: Molecular cancer therapeutics. 18(12)

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Mice, Nude, 03 medical and health sciences, Mice, 0302 clinical medicine, medicine, Animals, Humans, Kinome, Receptor, Fibroblast Growth Factor, Type 4, Kinase activity, Receptor, Kinase, business.industry, Liver Neoplasms, FGF19, Fibroblast growth factor receptor 4, medicine.disease, Fibroblast Growth Factors, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Cancer research, Signal transduction, business, Signal Transduction

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5ddb66996e7002e1cf057f14bbb2a55Test
    https://pubmed.ncbi.nlm.nih.gov/31409633Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث